• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Nature >Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.
【24h】

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells.

机译：ErbB2对白细胞介素6信号在前列腺癌细胞中的需求。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2eu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL-6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.
机译：白细胞介素-6（IL-6）是一种细胞因子，最初被认为是免疫和炎症反应的调节剂，但它也调节许多肿瘤细胞的生长，包括前列腺癌。生长因子受体ErbB2 / neu和ErbB3的过表达与前列腺癌的肿瘤转化有关。在这里，我们显示用IL-6治疗前列腺癌细胞系LNCaP会诱导ErbB2和ErbB3的酪氨酸磷酸化，但不会诱导ErbB1 / EGFR。我们还显示，ErbB2与IL-6受体的gp130亚基形成IL-6依赖性的复合物。这种关联很重要，因为对ErbB2活性的抑制导致IL-6诱导的MAPK激活被取消。因此，ErbB2是通过MAP激酶途径的IL-6信号传导的关键组成部分。这些数据表明细胞因子受体如何通过与生长因子受体激酶结合而使其信号途径多样化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号